Option chain shows key data for Galmed Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock, Option Chain

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Nvidia,Logo,On,Mobile,Phone,Screen,Company,Shares,Rise,Or

APLD

CNEY

GOVX

IMRX

LUMN

NDRA

SMMT

TNON

A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

ASTS

BYND

COIN

GOOGL

SHOP

Stocks got a boost as the Federal Reserve cut interest rates. However, the 50-basis point (0.5%) cut was larger than many analysts expected. That puts the focus on the future pace of rate cuts. Specifically, could the

MarketBeat Week in Review – 9/16 - 9/20

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals Ltd

Small Cap

Press Releases

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Comments

Galmed Pharmaceuticals

Galmed Pharmaceuticals (GLMD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga